Results 51 to 60 of about 9,990,963 (401)

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

Journal of Hematology & Oncology, 2020
VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized.
Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai, Tingbo Liang   +7 more
doaj   +1 more source

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance We describe a biobank of patient-derived pancreatic cancer organoids, characterized by whole-genome DNA sequencing, RNA sequencing, and histology.
E. Driehuis, E. Driehuis, A. Hoeck, A. Hoeck, Kat S. Moore, S. Kolders, Sigrid Kolders, Hayley E. Francies, M. Gulersonmez, E. Stigter, B. Burgering, Veerle Geurts, Veerle Geurts, A. Gračanin, G. Bounova, F. Morsink, R. Vries, S. Boj, J. V. Es, J. V. Es, G. Offerhaus, O. Kranenburg, M. Garnett, L. Wessels, Edwin Cuppen, Edwin Cuppen, L. Brosens, H. Clevers, Hans Clevers   +28 more
semanticscholar   +1 more source

Pancreatic Cancer: A Review.

Journal of the American Medical Association (JAMA), 2021
Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-
Wungki Park, A. Chawla, E. O’Reilly
semanticscholar   +1 more source

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study

BMC Cancer, 2022
Background Prognosis for patients recurred rapidly after resection of pancreatic ductal adenocarcinoma (PDAC) was extremely poor. We proposed the concept of postoperative hyper-progression disease (PO-HPD) to define recurrence within 2 months after ...
Siyi Zou, Xinjing Wang, Haoda Chen, Jiewei Lin, Chenlei Wen, Qian Zhan, Hao Chen, Xiongxiong Lu, Xiaxing Deng, Baiyong Shen   +9 more
doaj   +1 more source

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology, 2022
BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with poor prognosis. Karyopherin subunit alpha 4 (KPNA4) is a nuclear transport factor and plays tumor-promoting roles in multiple cancers.
Jingpiao Bao, Jingpiao Bao, Chaoliang Xu, Bin Li, Bin Li, Zengkai Wu, Zengkai Wu, Jie Shen, Jie Shen, Pengli Song, Pengli Song, Qi Peng, Qi Peng, Guoyong Hu, Guoyong Hu   +14 more
doaj   +1 more source

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Boeck, Stefan, Bruns, Christiane J., Heinemann, Volker, Jauch, Karl-Walter, Sargent, Mirja, Schäfer, Claus, Seufferlein, Thomas   +6 more
core   +1 more source

Evidence for a Causal Relationship Between Early Exocrine Pancreatic Disease and Cystic Fibrosis–Related Diabetes: A Mendelian Randomization Study

Diabetes, 2014
Circulating immunoreactive trypsinogen (IRT), a biomarker of exocrine pancreatic disease in cystic fibrosis (CF), is elevated in most CF newborns. In those with severe CF transmembrane conductance regulator (CFTR) genotypes, IRT declines rapidly in the ...
David Soave, Melissa R. Miller, K. Keenan, Weili Li, Jiafen Gong, W. Ip, F. Accurso, Lei Sun, J. Rommens, M. Sontag, P. Durie, L. Strug   +11 more
semanticscholar   +1 more source

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

New England Journal of Medicine, 2022
BACKGROUND KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.
J. Strickler, H. Satake, T. George, R. Yaeger, A. Hollebecque, I. Garrido-Laguna, M. Schuler, T. Burns, A. Coveler, G. Falchook, M. Vincent, Y. Sunakawa, L. Dahan, D. Bajor, S. Rha, C. Lemech, D. Juric, M. Rehn, G. Ngarmchamnanrith, Pegah Jafarinasabian, Q. Tran, D. Hong   +21 more
semanticscholar   +1 more source

Quality of Life in Chronic Pancreatitis is Determined by Constant Pain, Disability/Unemployment, Current Smoking, and Associated Co-Morbidities [PDF]

, 2017
OBJECTIVES: Chronic pancreatitis (CP) has a profound independent effect on quality of life (QOL). Our aim was to identify factors that impact the QOL in CP patients.
Abberbock, Judah, Alkaade, Samer, Amann, Stephen T., Anderson, Michelle A., Baillie, John, Banks, Peter A., Brand, Randall E., Conwell, Darwin L., Cote, Gregory A., Forsmark, Christopher E., Gardner, Timothy B., Gelrud, Andres, Guda, Nalini M., Lewis, Michele D., Machicado, Jorge D., Muniraj, Thiruvengadam, Sandhu, Bimaljit S., Sherman, Stuart, Singh, Vikesh K., Slivka, Adam, Tang, Gong, Whitcomb, David C., Wilcox, C. Mel, Yadav, Dhiraj   +23 more
core   +2 more sources

Haemorrhage in pancreatic disease

Journal of British Surgery, 1989
Abstract Haemorrhage is a life-threatening complication in pancreatic disease. Twenty-five patients with this complication are described; 15 had major bleeding, nine had minor bleeding and one patient had a pseudoaneurysm identified at operation.
S. Shankar, R. C. G. Russell
openaire   +3 more sources